(Total Views: 160)
Posted On: 09/18/2019 4:06:46 PM
Post# of 1354
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Featured on Stock Day with Everett Jolley to Discuss Advancements in Proprietary Platforms
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its President and CEO Richard T. Schumacher was recently featured on The Stock Day Podcast hosted by Everett Jolley. During the interview, Schumacher discussed PBIO and the company’s recent achievements. “A year ago, PBIO had one revenue-generating division. We now have three, each based on our proprietary PCT, BaroFold, or UST platforms,” PBIO President and CEO Richard T. Schumacher said in the podcast. “Our PCT platform supports our primary business, which is selling pressure-based instruments and consumables to research laboratories worldwide. Our customers include some of the world’s foremost protein chemists, working in many of the finest academic, government, biotech, and pharma laboratories around the globe. These scientists use PCT systems for a number of different protein, RNA, and DNA applications as they search to find new biomarkers of disease, diagnostic tools, druggable targets, and therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its President and CEO Richard T. Schumacher was recently featured on The Stock Day Podcast hosted by Everett Jolley. During the interview, Schumacher discussed PBIO and the company’s recent achievements. “A year ago, PBIO had one revenue-generating division. We now have three, each based on our proprietary PCT, BaroFold, or UST platforms,” PBIO President and CEO Richard T. Schumacher said in the podcast. “Our PCT platform supports our primary business, which is selling pressure-based instruments and consumables to research laboratories worldwide. Our customers include some of the world’s foremost protein chemists, working in many of the finest academic, government, biotech, and pharma laboratories around the globe. These scientists use PCT systems for a number of different protein, RNA, and DNA applications as they search to find new biomarkers of disease, diagnostic tools, druggable targets, and therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
